Recent Research Analysts’ Ratings Updates for Five Prime Therapeutics (FPRX)

A number of firms have modified their ratings and price targets on shares of Five Prime Therapeutics (NASDAQ: FPRX) recently:

  • 2/14/2018 – Five Prime Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. “
  • 2/8/2018 – Five Prime Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. “
  • 2/5/2018 – Five Prime Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 2/2/2018 – Five Prime Therapeutics was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 1/31/2018 – Five Prime Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. “
  • 1/30/2018 – Five Prime Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 1/25/2018 – Five Prime Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. “
  • 1/18/2018 – Five Prime Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 12/21/2017 – Five Prime Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Shares of Five Prime Therapeutics Inc (NASDAQ FPRX) opened at $19.09 on Thursday. Five Prime Therapeutics Inc has a 12-month low of $17.05 and a 12-month high of $49.30. The stock has a market cap of $637.02, a price-to-earnings ratio of -3.77 and a beta of 3.56.

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Receive News & Ratings for Five Prime Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply